Last reviewed · How we verify
NCT06304623: SVFCOVID-19
SVF for Treating Pulmonary Fibrosis Post COVID-19
Phase 1 trial testing Autologous adipose-derived SVF IV administration in Pulmonary Fibrosis in 40 participants. Completed in 1 March 2024.
1 March 2024
Quick facts
| Lead sponsor | Michael H Carstens |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 5 May 2020 |
| Primary completion | 1 March 2024 |
| Estimated completion | 1 March 2024 |
| Sites | 2 locations across Nicaragua |
Drugs / interventions tested
- Autologous adipose-derived SVF IV administration — full drug profile →
Conditions studied
- Pulmonary Fibrosis — all drugs for Pulmonary Fibrosis →
Sponsor
Michael H Carstens — full company profile →
Who can join
Adults 18 to 85, any sex, with Pulmonary Fibrosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
General description of the study This is a prospective, multicenter, expanded access interventional study of subjects recovered from COVID-19 pneumonia to assess their response to intravenous administration of adipose-derived autologous SVF. Primary objective The purpose of this study was to evaluate the safety of single intravenous injections of autologous adipose-derived SVF produced using the GID SVF-2 device system for the treatment of secondary respiratory distress associated with COVID-19. Secondary objective To evaluate the efficacy of the initial treatment with SVF IV.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06304623
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pulmonary Fibrosis
Currently open trials in the same condition.
- NCT07464132 — Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases · Phase 1, PHASE2 · recruiting
- NCT07396467 — Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis · active not recruiting
- NCT06912659 — The BALANCE Study: A Study in Spain to Find Out Whether a Patient Support Program Helps People With Pulmonary Fibrosis W · active not recruiting
- NCT06685874 — Interstitial Lung Disease Exacerbations Study · active not recruiting
- NCT06532071 — Advanced Imaging for Pulmonary Fibrosis · Phase 2 · recruiting
Other Michael H Carstens trials
Trials by the same sponsor.
- NCT06373809 — Placenta Derived Stem Cells for Treating of Chronic Ulcers and Neuropathy · EARLY_PHASE1 · completed
- NCT07259993 — Knee Osteoarthritis With Stromal Vascular Fraction Cells · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06304623 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Michael H Carstens
- Last refreshed: 12 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06304623.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing